Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States.
Flawless balance sheet with limited growth.
Share Price & News
How has Spero Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 2HA's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: 2HA underperformed the German Biotechs industry which returned 5.5% over the past year.
Return vs Market: 2HA underperformed the German Market which returned 8.3% over the past year.
Price Volatility Vs. Market
How volatile is Spero Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Spero Therapeutics undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate 2HA's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate 2HA's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: 2HA is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: 2HA is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 2HA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 2HA is good value based on its PB Ratio (1.9x) compared to the DE Biotechs industry average (3.5x).
How is Spero Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 2HA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 2HA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 2HA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 2HA's revenue (58.4% per year) is forecast to grow faster than the German market (5.1% per year).
High Growth Revenue: 2HA's revenue (58.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 2HA's Return on Equity is forecast to be high in 3 years time
How has Spero Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 2HA is currently unprofitable.
Growing Profit Margin: 2HA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 2HA is unprofitable, and losses have increased over the past 5 years at a rate of -17.4% per year.
Accelerating Growth: Unable to compare 2HA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 2HA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).
Return on Equity
High ROE: 2HA has a negative Return on Equity (-50.02%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
How is Spero Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: 2HA's short term assets ($104.0M) exceed its short term liabilities ($15.1M).
Long Term Liabilities: 2HA's short term assets ($104.0M) exceed its long term liabilities ($4.4M).
Debt to Equity History and Analysis
Debt Level: 2HA is debt free.
Reducing Debt: 2HA has not had any debt for past 5 years.
Inventory Level: 2HA has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if 2HA's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 2HA has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 2HA has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of -22.7% each year.
What is Spero Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate 2HA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate 2HA's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 2HA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 2HA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 2HA's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Ankit Mahadevia (38yo)
Mr. Ankit Mahadevia, MD, MBA serves as the Chief Executive Officer and President of Spero Therapeutics, LLC. Mr. Mahadevia Co-founded of Spero Therapeutics, Inc. in 2013 and has been its Chief Executive Of ...
CEO Compensation Analysis
Compensation vs Market: Ankit's total compensation ($USD721.32K) is about average for companies of similar size in the German market ($USD626.29K).
Compensation vs Earnings: Ankit's compensation has been consistent with company performance over the past year.
|Chief Operating Officer||2.4yrs||US$533.80k||0.0078% $12.8k|
|Chief Medical Officer||2.1yrs||US$1.63m||no data|
|Interim CFO & Treasurer||0.3yrs||no data||no data|
|Chief Scientific Officer||5.8yrs||US$450.89k||no data|
|Senior Director of Investor Relations||0yrs||no data||no data|
|Vice President of People Strategy & Culture||1.3yrs||no data||no data|
|Head of Clinical Microbiology||1.8yrs||no data||no data|
|Head of Clinical Operations||2.1yrs||no data||no data|
Experienced Management: 2HA's management team is considered experienced (2.1 years average tenure).
|Independent Director||6.9yrs||US$92.15k||no data|
|Independent Director||2.6yrs||US$102.15k||no data|
|Scientific Advisors||5.8yrs||no data||no data|
|Clinical Advisor||5.8yrs||no data||no data|
|Scientific Advisor||0yrs||no data||no data|
|Independent Director||4.4yrs||US$100.65k||no data|
|Clinical Advisor||5.8yrs||no data||no data|
|Clinical Advisor||5.8yrs||no data||no data|
Experienced Board: 2HA's board of directors are considered experienced (5.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 28.3%.
Spero Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Spero Therapeutics, Inc.
- Ticker: 2HA
- Exchange: DB
- Founded: 2013
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$177.700m
- Listing Market Cap: US$163.715m
- Shares outstanding: 19.13m
- Website: https://sperotherapeutics.com
Number of Employees
- Spero Therapeutics, Inc.
- 675 Massachusetts Avenue
- 14th Floor
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|SPRO||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Nov 2017|
|2HA||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Nov 2017|
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is phase I clinical trial to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic, which is in phase I clinical trial for the treatment of pulmonary non-tuberculous mycobacterial infections. Spero Therapeutics, Inc. has collaboration agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries, as well as has option to rights to SPR741 in the territory; and collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/24 23:50|
|End of Day Share Price||2020/02/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.